These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21338679)

  • 1. Fever following administration of two inactivated influenza vaccines--a survey of parents of New Zealand infants and children 5 years of age and under.
    Petousis-Harris H; Poole T; Booy R; Turner N
    Vaccine; 2011 Apr; 29(16):2933-7. PubMed ID: 21338679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance.
    Petousis-Harris H; Poole T; Turner N; Reynolds G
    Vaccine; 2012 Jul; 30(33):4945-52. PubMed ID: 22664224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Aug; 59(31):989-92. PubMed ID: 20703207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.
    Leeb A; Carcione D; Richmond PC; Jacoby P; Effler PV
    Vaccine; 2011 Oct; 29(45):7920-4. PubMed ID: 21864621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.
    Blyth CC; Currie AJ; Wiertsema SP; Conway N; Kirkham LA; Fuery A; Mascaro F; Geelhoed GC; Richmond PC
    Vaccine; 2011 Jul; 29(32):5107-13. PubMed ID: 21640152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010.
    Kelly H; Carcione D; Dowse G; Effler P
    Euro Surveill; 2010 Sep; 15(37):. PubMed ID: 20929647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events.
    Dey A; Gidding HF; Menzies R; McIntyre P
    Vaccine; 2014 Apr; 32(19):2204-8. PubMed ID: 24613527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of inactivated trivalent influenza vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Shah SI; Caprio M; Hendricks-Munoz K
    Pediatrics; 2007 Sep; 120(3):e617-21. PubMed ID: 17766502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.
    Salleras L; Domínguez A; Pumarola T; Prat A; Marcos MA; Garrido P; Artigas R; Bau A; Brotons J; Bruna X; Català P; Carreras E; Cuadra D; Gatell A; Millet S; Oller J; Raga E
    Vaccine; 2006 Nov; 24(44-46):6638-42. PubMed ID: 16842892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children.
    Li-Kim-Moy J; Yin JK; Rashid H; Khandaker G; King C; Wood N; Macartney KK; Jones C; Booy R
    Euro Surveill; 2015 Jun; 20(24):. PubMed ID: 26111238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia.
    Wood N; Sheppeard V; Cashman P; Palasanthiran P; Casacelli M; Cannings K; McIntyre P
    Pediatr Infect Dis J; 2012 Feb; 31(2):199-202. PubMed ID: 22094632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
    Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.
    Lambert SB; Chuk LM; Nissen MD; Nolan TM; McVernon J; Booy R; Heron L; Richmond PC; Walls T; Marshall HS; Reynolds GJ; Hartel GF; Hu W; Lai MH
    Influenza Other Respir Viruses; 2013 Sep; 7(5):676-85. PubMed ID: 23551933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-dose influenza vaccine.
    Wyatt KN; Ryan GJ; Sheerin KA
    Ann Pharmacother; 2006 Sep; 40(9):1635-9. PubMed ID: 16835314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study.
    Walter EB; Englund JA; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2009 Dec; 28(12):1099-104. PubMed ID: 19935270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine.
    McMahon AW; Iskander JK; Haber P; Braun MM; Ball R
    Vaccine; 2008 Jan; 26(3):427-9. PubMed ID: 18093701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual report: surveillance of adverse events following immunisation in Australia, 2010.
    Mahajan D; Cook J; McIntyre PB; Macartney K; Menzies RI
    Commun Dis Intell Q Rep; 2011 Dec; 35(4):263-80. PubMed ID: 22624487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.